10189-45-4

Upstream product

• 49609-84-9 2-Chloronicotinoyl chloride 
• 95-55-6 2-amino-phenol 
• 74-88-4 methyl iodide 
• 53981-24-1 2-amino-5-fluorophenol 
• 121495-79-2 2-chloropyridine-3-carbonyl chloride hydrochloride 

Downstream Products

• 134894-49-8 6-methylbenzo[b]pyrido[3,2-f ][1,4]oxazepin-5(6H)-one 
• 134894-51-2 10-Allyl-10H-5-oxa-4,10-diaza-dibenzo[a,d]cyclohepten-11-one 
• 134894-50-1 10-Ethyl-10H-5-oxa-4,10-diaza-dibenzo[a,d]cyclohepten-11-one 
• 858675-09-9 2-chloro-N-(2-(1-methyl-2-oxo-n-propoxy)-phenyl)-nicotinic acid amide 

Relevant academic research and scientific papers

Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase

This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

INHIBITORS OF HISTONE DEACETYLASE

Compounds which are histone deacetylase inhibitors and their use in treating various disorders, including Alzheimer's Disease.

INHIBITORS OF HISTONE DEACETYLASE

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the inven- tion provides for compounds of formula (I) wherein (B), Q, J, L and Z are as defined in the specification

(Hetero)cyclyl carboxanilides for controlling harmful fungi

The present invention relates to (hetero)cyclylcarboxanilides of the formula I, in which n is 0, 1, 2, 3 or 4; and m is 1, 2 or 3, Y is oxygen or sulfur; A is unsubstituted or substituted phenyl or is an at least monounsaturated, unsubstituted or substitu

(HETERO)CYCLYL CARBOXANILIDES FOR CONTROLLING HARMFUL FUNGI

The invention relates to (hetero)cyclyl carboxanilides of general formula (I), wherein n represents 0, 1, 2, 3, or 4, m represents 1, 2, or 3, Y represents oxygen or sulfur, A represents optionally substituted phenyl or an at least monounsaturated, optionally substituted five-membered or six-membered heterocycle, and R1, R2, R3m, R4, R5, and R6 have the meanings indicated in claim 1, and the agriculturally useful salts thereof. The invention further relates to the use of said (hetero)cyclyl carboxanilides of general formula (I) and the agriculturally useful salts thereof as fungicides as well as plant protection agents containing the same.

Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study

In order to characterize the pharmacological profile of the different chemical classes of pyridobenzazepine derivatives, a series of N- methylpiperazinopyrido[1,4]- and -[1,5]- benzoxa- and benzothiazepine derivatives were prepared. The affinities for D2, D1, 5-HT2, and cholinergic (M) receptors were measured. In comparison to dibenzazepine reference compounds, a strong decrease of the affinities was observed, less pronounced, however, for the substituted analogues. Oxazepine and thiazepine analogues like clozapine (except 8-chloro-6-(4-methylpiperazin-1-yl)- pyrido[2,3-b][1,4]benzoxazepine (9) and 8-chloro-6-(4-methylpiperazin-1- yl)pyrido[2,3-b][1,4]-benzothiazepine (11)) were found to be inactive against apomorphine stereotypies. In the open-field test in rats, different molecules showed a high disinhibitory activity as observed with anxiolytic drugs. Moreover, 8-chloro-5-(4-methylpiperazin-1-yl)pyrido[2,3-b][1,5]benzoxazepine (14) presented a clozapine-like profile that was confirmed in the behavioral model in dogs and showed most of the behavioral characteristics described for antipsychotic drugs. Its neurochemical profile, in particular the 5-HT2/D2 ratio, was also compatible with atypical antipsychotic activity.

Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones

Dibenzoxazepin-11(10H)-ones (III), pyridobenzoxazepin-6(5H)-ones (IV), and pyridobenzoxazepin-5(6H)-ones (V) were found to inhibit human immunodeficiency virus type 1 reverse transcriptase with IC50 values as 19 nM.A-ring substitution has a profound effect on activity, with appropriate substituents at the positions ortho and para to the lactam nitrogen providing dramatically enhanced potency.Substitution in the C-ring is generally neutral or detrimental to activity.Although a C-ring amino substituent at the position meta to the lactam carbonyl is generally beneficial to activity, it has essentially no effect when the A-ring is optimally substituted.Like the dipyridodiazepinone nevirapine, compounds III-V are specific for HIV-1 RT, exhibiting no inhibitory activity against HIV-2 RT or other virial reverse transcriptase enzymes.